Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22612668 | 0.87 | GSR (0.55) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL21879356 | 0.87 | DPP8 (0.51) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL31722025 | 0.87 | GSR (0.55) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL14906253 | 0.87 | GSR (0.55) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL28000252 | 0.87 | GSR (0.55) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL120711 | 0.83 | DPP7 (0.54) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL30569498 | 0.82 | DPP8 (0.50) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL29985350 | 0.82 | GSR (0.49) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL29374543 | 0.82 | GSR (0.49) | DPP8DPP9DPP7GNAI3GNAO1 | |
| Acetic Acid SCHEMBL25216563 | 0.82 | FOLH1 (0.46) | DPP8DPP9DPP7GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150306084-A1 | ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | BAYER IP GMBH (DE) | 2015-10-29 | — | — | US | disclosed |
| US-9040566-B2 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-20130210797-A1 | ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20120058983-A1 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210797-A1 | ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | ADORA1, ADORA3, ADORA2A | DPP8 829/4885DPP9 657/4885DPP7 749/4885 |
| US-20120058983-A1 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | ADORA1, ADORA3, ADORA2A | DPP8 829/4885DPP9 657/4885DPP7 749/4885 |
| US-20150306084-A1 | ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | ADORA1, ADORA3, ADORA2A | DPP8 829/4885DPP9 657/4885DPP7 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.